The MDR phenotype is associated with the expression of COX-2 and iNOS in a human hepatocellular carcinoma cell line

Hepatology

Volumn 35, Issue 4, 2002, Pages 843-852

  Fantappiè, Ornella ^a   Masini, Emanuela ^b   Sardi, Iacopo ^b   Raimondi, Laura ^b   Bani, Daniele ^b   Solazzo, Michela ^a   Vannacci, Alfredo ^b   Mazzanti, Roberto ^a  

^a CAREGGI UNIVERSITY HOSPITAL   (Italy)

^b UNIVERSITY OF FLORENCE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CELECOXIB; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; EPIDERMAL GROWTH FACTOR; LIPOPOLYSACCHARIDE; NIMESULIDE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; PROSTAGLANDIN; RNA;

ANGIOGENESIS; ARTICLE; CANCER CELL CULTURE; CANCER RESISTANCE; CELL PROLIFERATION; CONTROLLED STUDY; CORRELATION ANALYSIS; HUMAN; HUMAN CELL; LIVER CELL CARCINOMA; MULTIDRUG RESISTANCE; NORTHERN BLOTTING; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; WESTERN BLOTTING;

EID: 0036208533     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1053/jhep.2002.32469     Document Type: Article

References (56)

1. Multidrug resistance: Molecular mechanisms and clinical relevance
2. The mdr1 gene, responsible for multidrug-resistance, codes for P-glycoprotein
3. P-glycoprotein and multidrug resistance
4. Benzquinamide inhibits P-glycoprotein mediated drug efflux and potentiates anticancer agent cytotoxicity in multidrug resistant cells
5. Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues
6. MDR1 RNA expression is an independent prognostic factor in acute myeloid leukemia
7. p53 and P-glycoprotein are often co-expressed and are associated with poor prognosis in breast cancer
8. Multidrug resistance in lymphomas
9. Quantitation of sinusoidlike vessels in hepatocellular carcinoma: Its clinical and prognostic significance
10. Expression of vascular endothelial growth factor in surgical specimens of hepatocellular carcinoma
11. Prognostic value of bone marrow angiogenesis in multiple myeloma
12. MDR1 (multidrug resistance) gene expression in human primary liver cancer and cirrhosis
13. p53 and vascular endothelial growth of NOS2-expressing human carcinoma cells
14. Cox-2, iNOS and p53 as playmarkers of tumor angiogenesis
15. Cyclooxygenase-2 expression is related to prostaglandin biosynthesis and angiogenesis in human gastric cancer
16. Effect of NO, vasodilator prostaglandins, and adenosine on skeletal muscle angiogenic growth factor gene expression
17. Cyclooxygenase regulates angiogenesis induced by colon cancer cells
18. Nitric oxide is an upstream signal of vascular endothelial growth factor-induced extracellular signal-regulated kinase 1/2 activation in postcapillary endothelium
19. Role of nitric oxide in angiogenesis and tumor progression in head and neck cancer
20. Hepatitis B surface antigen produced by a human hepatoma cell line
21. Quantitative image analysis of rhodamine 123 transport by adriamycinsensitive and -resistant NIH 3T3 and human hepatocellular carcinoma (Alexander) cells
22. 2 and other cyclic AMP stimulants in J774 macrophages
23. Relaxin activates the L-arginine-nitric oxide pathway in vascular smooth muscle cells in culture
24. Metabolism of glyceril trinitrate to nitric oxid by endothelial cells and smooth muscle cells and its induction by Escherichia coli lipopolysaccharide
25. Effects of OKY 046 a tromboxane-synthase inhibitor, on renal function in nonazotemic cirrhotic patients with ascites
26. Protein measurement with the folin phenol reagent
27. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform
28. Steroid hormone receptor immunohistochemistry and amplification of c-myc protooncogene. Relationship to disease-free survival in breast cancer
29. Relaxin activates the L-arginine-nitric oxide pathway in human breast cancer cells
30. Oxidative damage of cardiomyocytes is limited by extracellular regulated kinases 1/2-mediated induction of cyclooxygenase-2
31. Differential in vitro sensitivity of human tumor and normal cells to chemotherapeutic agents and resistance modulators
32. Cyclo-oxygenase-2 enhances basic fibroblast growth factor-induced angiogenesis through induction of vascular endothelial growth factor in rat sponge implants
33. Predominant role of endothelial nitric oxide synthase in vascular endothelial growth factor-induced angiogenesis and vascular permeability
34. Antiangiogenesis efficacy of nitric oxide donors
35. Endogenously produced nitric oxide inhibits endothelial cell growth as demonstrated using novel antisense cell lines
36. Ras-dependent and -independent regulation of reactive oxygen species by mitogenic growth factors and TGF-betal
37. LPS induces Rac1-dependent reactive oxygen species (ROS) formation and coordinates TNF-α secretion through IKK regulation of NF-kappa B
38. The antioxidant paradox
39. Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2
40. 2 in human colon cancer cells
41. Susceptibility to lipid peroxidation of human hepatocellular carcinoma cell lines with different levels of multiple drug-resistant phenotype
42. Nitric oxide activates cyclooxygenase enzymes
43. Regulation of cyclooxygenase enzyme by nitric oxide
44. Nitric oxide: An inhibitor of NF-κB/Rel system in glial cells
45. 6-(1-iminoethyl)lysine: A selective inhibitor of inducible nitric oxide synthase
46. Growth factor-dependent phosphoinositide signaling
47. Expression of the multidrug-resistance 1 (MDR1) gene and prognosis in human pancreatic cancer
48. Relationship of P-glycoprotein and carcinoembryonic antigen expression in human colon carcinoma to local invasion, DNA ploidy, and disease relapse
49. Expression of cyclooxygenase-2 in human hepatocellular carcinoma: Relevance to tumor dedifferentiation
50. Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinoma
51. Increased expression of inducible nitric oxide synthase and ciclooxygenase-2 in Barrett's esophagus and associated adenocarcinomas
52. Expression of cyclooxygenase-1 and -2 in human colorectal cancer
53. Cyclooxygenase-2 expression in human colon cancer cells increases metastatic potential
54. Meloxicam inhibits the growth of non-small cell lung cancer
55. Chemoprevention of colon cancer by specific cyclooxygenase-2 inhibitor, celecoxib, administered during different stages of carcinogenesis
56. The physical properties of nitric oxide, critical determinants of its biological actions